Researchers Announce Phase II Trial Results of Dasatinib for Leukemia

by: cancercompass

Dasatinib is an effective treatment for patients with chronic myelogenous leukemia in an accelerate phase (CML-AP) when imatinib treatments fail, suggests a recent study published in the Journal of Clinical Oncology.

This phase II trial study explored the safety of dasatinib by prescribing 174 imatinib-resistant patients 70 mg of the drug in oral form twice daily.

Researchers reported the 12 month progression-free survival and overall survival rates were 66% and 82%, respectively. Dasatinib was well tolerated with the most frequent side effects being diarrhea, cytopenias, as well as pleural effusion.